WO2003094859A3 - Epha2 monoclonal antibodies and methods of use thereof - Google Patents

Epha2 monoclonal antibodies and methods of use thereof Download PDF

Info

Publication number
WO2003094859A3
WO2003094859A3 PCT/US2003/015044 US0315044W WO03094859A3 WO 2003094859 A3 WO2003094859 A3 WO 2003094859A3 US 0315044 W US0315044 W US 0315044W WO 03094859 A3 WO03094859 A3 WO 03094859A3
Authority
WO
WIPO (PCT)
Prior art keywords
epha2
methods
cancer
binds
antibody
Prior art date
Application number
PCT/US2003/015044
Other languages
French (fr)
Other versions
WO2003094859A2 (en
Inventor
Michael S Kinch
Kelly Carles-Kinch
Peter Kiener
Solomon Langermann
Original Assignee
Medimmune Inc
Michael S Kinch
Kelly Carles-Kinch
Peter Kiener
Solomon Langermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc, Michael S Kinch, Kelly Carles-Kinch, Peter Kiener, Solomon Langermann filed Critical Medimmune Inc
Priority to AU2003243228A priority Critical patent/AU2003243228B2/en
Priority to ES03750125T priority patent/ES2373715T3/en
Priority to JP2004502947A priority patent/JP4557714B2/en
Priority to CA002485373A priority patent/CA2485373A1/en
Priority to EP03750125A priority patent/EP1519956B1/en
Priority to AT03750125T priority patent/ATE525398T1/en
Publication of WO2003094859A2 publication Critical patent/WO2003094859A2/en
Publication of WO2003094859A3 publication Critical patent/WO2003094859A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 pho 3phorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to Eph A2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network fore cation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low Koff, thereby, inhibiting tumor cell growth and/or metastasis. The invention also provides pharmaceutical compositions comprising one or more EphA2 antil)odies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
PCT/US2003/015044 2002-05-10 2003-05-12 Epha2 monoclonal antibodies and methods of use thereof WO2003094859A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003243228A AU2003243228B2 (en) 2002-05-10 2003-05-12 EphA2 monoclonal antibodies and methods of use thereof
ES03750125T ES2373715T3 (en) 2002-05-10 2003-05-12 MONOCLONAL ANTIBODIES AGAINST EPHA2 AND PROCEDURES FOR THE SAME USE.
JP2004502947A JP4557714B2 (en) 2002-05-10 2003-05-12 EphA2 monoclonal antibody and method of use thereof
CA002485373A CA2485373A1 (en) 2002-05-10 2003-05-12 Epha2 monoclonal antibodies and methods of use thereof
EP03750125A EP1519956B1 (en) 2002-05-10 2003-05-12 Epha2 monoclonal antibodies and methods of use thereof
AT03750125T ATE525398T1 (en) 2002-05-10 2003-05-12 EPHA2 MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHOD

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37932202P 2002-05-10 2002-05-10
US60/379,322 2002-05-10
US41821302P 2002-10-14 2002-10-14
US60/418,213 2002-10-14
US46050703P 2003-04-03 2003-04-03
US60/460,507 2003-04-03

Publications (2)

Publication Number Publication Date
WO2003094859A2 WO2003094859A2 (en) 2003-11-20
WO2003094859A3 true WO2003094859A3 (en) 2005-02-03

Family

ID=29424523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/015044 WO2003094859A2 (en) 2002-05-10 2003-05-12 Epha2 monoclonal antibodies and methods of use thereof

Country Status (8)

Country Link
US (3) US20040028685A1 (en)
EP (1) EP1519956B1 (en)
JP (2) JP4557714B2 (en)
AT (1) ATE525398T1 (en)
AU (2) AU2003243228B2 (en)
CA (1) CA2485373A1 (en)
ES (1) ES2373715T3 (en)
WO (1) WO2003094859A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
EP1519956B1 (en) * 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
ATE530577T1 (en) * 2002-05-10 2011-11-15 Purdue Research Foundation EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF APPLICATION THEREOF
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
JP2006501153A (en) * 2002-05-23 2006-01-12 パーデュー・リサーチ・ファウンデーション Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
EP1605961A4 (en) 2003-03-12 2009-11-11 Vasgene Therapeutics Inc Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR20110094361A (en) 2003-04-11 2011-08-23 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
WO2004092343A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 and non-neoplastic hyperproliferative cell disorders
CA2525929A1 (en) * 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
CA2528549A1 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
US7173015B2 (en) * 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
AU2004280333A1 (en) * 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
EP1689346A4 (en) * 2003-11-20 2007-11-21 Medimmune Inc Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
WO2005067460A2 (en) * 2003-12-24 2005-07-28 Medimmune, Inc. Epha2 vaccines
DE102004010050A1 (en) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Specific monoclonal and polyclonal antibodies to repinotan and its ring-open form
DE602005025459D1 (en) 2004-03-12 2011-02-03 Vasgene Therapeutics Inc EPHB4-Binding Antibodies for the Inhibition of Angiogenesis and Tumor Growth
WO2005090406A2 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US8435959B2 (en) 2004-03-29 2013-05-07 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
WO2005117967A2 (en) 2004-04-12 2005-12-15 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
WO2006004663A2 (en) * 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
WO2006023420A2 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
AU2005286662B2 (en) 2004-09-23 2011-10-06 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2005295158A1 (en) * 2004-10-18 2006-04-27 Medimmune, Llc High cell density process for growth of Listeria
EP1831694A4 (en) * 2004-10-21 2008-12-17 Penn State Res Found Eph receptor tumor biomarkers
WO2006047638A2 (en) * 2004-10-27 2006-05-04 Medimmune, Inc. Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
JP2008518023A (en) 2004-10-27 2008-05-29 メディミューン,インコーポレーテッド Regulation of antibody specificity by altering affinity for cognate antigens
EP1814567A4 (en) * 2004-10-27 2009-05-06 Medimmune Inc Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections
CN104059150B (en) * 2005-02-04 2018-10-02 宏观基因有限公司 In conjunction with the antibody and its application method of EPHA2
CA2605068A1 (en) * 2005-04-15 2006-10-26 The Board Of Regents Of The University Of Texas System Delivery of sirna by neutral lipid compositions
KR20080025174A (en) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 Antibody formulations having optimized aggregation and fragmentation profiles
CN101228181B (en) * 2005-07-20 2013-09-18 默沙东公司 Hcv ns3 protease inhibitors
AU2006287416A1 (en) * 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
CN1870631B (en) * 2005-11-11 2010-04-14 华为技术有限公司 Gate control method of media gateway
US7803364B2 (en) * 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
CA2633718A1 (en) * 2005-12-21 2007-07-05 Medimmune, Llc Affinity optimized epha2 agonistic antibodies and methods of use thereof
KR101528939B1 (en) * 2006-07-18 2015-06-15 사노피 Antagonist antibody against epha2 for the treatment of cancer
JP2010530437A (en) * 2007-06-18 2010-09-09 メディミューン,エルエルシー Synergistic treatment of cells expressing EphA2 and ErbB2
DK2173378T3 (en) 2007-06-27 2014-05-12 Admune Therapeutics Llc COMPLEXES OF IL-15 AND IL-15RALFA AND APPLICATIONS THEREOF
EP2199390B1 (en) 2007-08-30 2016-12-21 Daiichi Sankyo Company, Limited Anti-epha2 antibody
JP2012525432A (en) * 2009-04-29 2012-10-22 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー Antibody with improved immunoreactivity with heregulin-conjugated HER3
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
AR078470A1 (en) 2009-10-02 2011-11-09 Sanofi Aventis ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
EP2556172A4 (en) 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
MX349662B (en) 2010-07-22 2017-08-08 Univ California Anti-tumor antigen antibodies and methods of use.
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
AU2012216627A1 (en) * 2011-11-14 2013-05-30 Newcastle Innovation Ltd. Composition and methods for the diagnosis, prognosis and treatment of leukemia
KR102364383B1 (en) 2014-05-29 2022-02-17 마크로제닉스, 인크. Tri-specific binding molecules and methods of use thereof
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
JPWO2018135653A1 (en) * 2017-01-23 2020-01-09 学校法人 東洋大学 Anti-EPHA2 antibody and immunological detection of EPHA2 using the same
MX2019009967A (en) 2017-02-24 2019-12-02 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof.
MX2020009743A (en) * 2018-03-19 2020-10-08 Abeome Corp High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof.
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
AU2020348861A1 (en) 2019-09-18 2022-01-27 Molecular Templates, Inc. PD-L1 binding molecules comprising Shiga toxin A Subunit scaffolds
EP4037711A4 (en) * 2019-10-03 2024-02-14 Atyr Pharma Inc Compositions and methods comprising anti-nrp2 antibodies
CN116693597A (en) * 2023-03-09 2023-09-05 南京大学 Method for nitrosation of tyrosine in phenol derivatives, polypeptides and proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031252A1 (en) * 2000-03-31 2001-10-18 Low Philip Stewart Method of treatment using ligand-immunogen conjugates

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31252A (en) * 1861-01-29 Improvement in iron ties for cotton-bales
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
JP3040121B2 (en) * 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69228300T2 (en) * 1991-08-22 1999-09-23 Becton Dickinson Co METHODS AND COMPOSITIONS FOR CANCER THERAPY AND FOR THE PREDICTABILITY OF REACTIONS TO THIS TREATMENT
EP0571613B1 (en) * 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5837448A (en) * 1992-05-15 1998-11-17 The Salk Institute For Biological Studies Protein-tyrosine kinase genes
JPH08505765A (en) * 1992-11-13 1996-06-25 アムジエン・インコーポレーテツド ECK receptor ligand
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
NZ258697A (en) * 1992-11-13 1996-03-26 Immunex Corp Elk-l polypeptide, coding sequence and vector therefor
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5814479A (en) * 1994-01-04 1998-09-29 Zhou; Renping Bsk receptor-like tyrosine kinase
JPH09512167A (en) * 1994-04-15 1997-12-09 アムジエン・インコーポレーテツド HEK5, HEK7, HEK8, HEK11, novel EPH-like receptor protein tyrosine kinase
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5795734A (en) * 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5876949A (en) * 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5795775A (en) * 1996-09-26 1998-08-18 Becton Dickinson And Company Culture vessel and assembly
US5761934A (en) * 1996-10-22 1998-06-09 Kuo; Li-Tsao Cable lock and an universal hold-down support
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
WO1999008696A1 (en) * 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
AU766077C (en) * 1998-11-20 2004-10-07 Genentech Inc. Uses for Eph receptor antagonists and agonists to treat vascular disorders
DE60027768T2 (en) * 1999-08-17 2007-04-05 Purdue Research Foundation, West Lafayette TREATMENT OF METASTATIC DISEASE
ATE483978T1 (en) * 1999-08-17 2010-10-15 Purdue Research Foundation ANTI-EPHA2 ANTIBODIES AS A CANCER DIAGNOSTIC
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU4139801A (en) * 1999-12-06 2001-06-12 Board Of Trustees Of The University Of Arkansas, The Controlled delivery of antigens
JP4992068B2 (en) * 2000-01-27 2012-08-08 メディミューン,エルエルシー Ultra high affinity neutralizing antibody
CA2401652A1 (en) * 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
PT1410011E (en) * 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
US20030119112A1 (en) * 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2003059182A (en) * 2001-08-10 2003-02-28 Teac Corp Recording method and apparatus for 1-bit form digital signal and accessory apparatus
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1519956B1 (en) * 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
ATE530577T1 (en) * 2002-05-10 2011-11-15 Purdue Research Foundation EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF APPLICATION THEREOF
AU2003278725A1 (en) * 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
JP2006507256A (en) * 2002-09-24 2006-03-02 ザ バーナム インスティチュート Novel drug that modulates Eph receptor activity
KR20110094361A (en) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 and non-neoplastic hyperproliferative cell disorders
AU2004229527B2 (en) * 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031252A1 (en) * 2000-03-31 2001-10-18 Low Philip Stewart Method of treatment using ligand-immunogen conjugates

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARLES-KINCH K ET AL: "Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior", CANCER RESEARCH, vol. 62, no. 10, 15 May 2002 (2002-05-15), pages 2840 - 2847, XP002904266 *
LU M ET AL: "EphA2 Overexpression Decreases Estrogen Dependence and Tamoxifen Sensitivity", CANCER RESEARCH, vol. 63, 15 June 2003 (2003-06-15), pages 3425 - 3429, XP002904267 *
PRATT R L ET AL: "Ligand binding up-regulates EphA2 mesenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway", MOLECULAR CELLULAR RESEARCH, vol. 1, December 2003 (2003-12-01), pages 1070 - 1076, XP009032924 *
WALKER-DANIELS J ET AL: "c-Cbl-Dependent EphA2 Protein Degradation Is Induced by Ligand Binding", MOLECULAR CELLULAR RESEARCH, vol. 1, November 2002 (2002-11-01), pages 79 - 87, XP002904268 *
ZANTEK N D ET AL: "E-cadherin regulates the functon of the EphA2 receptor tyrosine kinase", CELL GROWTH DIFFER, vol. 10, no. 9, September 1999 (1999-09-01), pages 629 - 638, XP000978524 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Also Published As

Publication number Publication date
EP1519956A4 (en) 2006-10-25
AU2003243228B2 (en) 2009-03-26
AU2009202542A1 (en) 2009-07-16
US20040028685A1 (en) 2004-02-12
JP4557714B2 (en) 2010-10-06
AU2003243228A1 (en) 2003-11-11
ATE525398T1 (en) 2011-10-15
EP1519956A2 (en) 2005-04-06
JP2010246546A (en) 2010-11-04
WO2003094859A2 (en) 2003-11-20
ES2373715T3 (en) 2012-02-08
US20100278838A1 (en) 2010-11-04
JP2005538701A (en) 2005-12-22
EP1519956B1 (en) 2011-09-21
US20070166314A1 (en) 2007-07-19
CA2485373A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
WO2003094859A3 (en) Epha2 monoclonal antibodies and methods of use thereof
WO2005048917A3 (en) Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
EP1575509A4 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
Pradelli et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs
WO2005051307A3 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2019220369A3 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
RU2006132466A (en) HIGHLY CONCENTRATED LIQUID COMPOSITIONS ANTI-EGFR ANTIBODIES
CA2633594C (en) Means and methods for the treatment of tumorous diseases
NL300418I1 (en) Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascitis
WO2002028481A3 (en) Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
EA201300022A1 (en) THERAPEUTIC HUMAN MONOCLONAL ANTIBODY AGAINST IL-1R1
EP0821728A4 (en) Tie-2 ligands, methods of making and uses thereof
IL180588A0 (en) Humanized anti-cmet antagonists
ECSP099770A (en) ANTI-TROP-2 HUMANIZED AND HYBRID ANTIBODIES THAT MEDITATE CANCEROSE CELL CYTO TOXICITY
WO2007053577A3 (en) Compositions and methods for diagnosing and treating cancer
NZ528624A (en) Antibodies against cancer
WO2008108910A3 (en) Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
Walthall Magistrate stamps on grain measures in early Hellenistic Sicily
Lee et al. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia
Mott et al. Melanoma associated with pseudoepitheliomatous hyperplasia: a case series and investigation into the role of epidermal growth factor receptor
SE0300098D0 (en) Use of cyclin D1 inhibitors
Avilés et al. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
EA200300468A1 (en) SUPPRESSION OF TUMOR CELL DEPENDENCE ON THE GROWTH FACTOR
JOP20190279A1 (en) Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2485373

Country of ref document: CA

Ref document number: 2004502947

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003243228

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003750125

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003750125

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)